Category: News

We will be at the BAD Annual Meeting in Glasgow from the 1st to the 3rd July - come visit us at our stand! You can also attend one of our talks: - Tuesday, 1st July at 10:30 - Prof Warren & Dr Oras Alabas - Hot Topics - Update on new data to inform clinicians on...

We have reopened recruitment to Taltz (ixekizumab). If a patient recently started on Taltz meets all of our eligibility criteria, they can be recruited. We will review patients who switched from the Conventional cohort onto Taltz, where we have paused...

Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...

BADBIR will be at the BAD Annual Meeting in Manchester, 2nd-4th JulyCome and visit us on our stand in the exhibition hall, or attend one of our talks:Tues 2nd July; 14:30-15:00: How BADBIR can help answer your research questionWeds 3rd July; 09:00-09:15:...

We are now accepting patients on Spevigo (spesolimab). Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP). BADBIR can accept registrations for patients with a GPP diagnosis.Please see the eligibility page for...

BADBIR is now open to registrations of patients commencing on the following drugs:Stelara (ustekinumab)Humira (adalimumab)Amgevita (adalimumab)Hulio (adalimumab)Hyrimoz (adalimumab)Idacio (adalimumab)Yuflyma (adalimumab)If a patient is already registered on BADBIR in...

In our ongoing commitment to maintaining a secure and user-friendly online environment, we are updating our password policy. We kindly request all our users to consider reviewing and enhancing the strength of their passwords in preparation for the new criteria, which...